Hexima Limited announced that it has completed enrolment of patients into its phase IIb clinical trial evaluating pezadeftide (HXP124) as a potential new topical treatment for onychomycosis. The study is on schedule and Hexima expects to announce results from the trial in second quarter of 2022. This is an important achievement in pezadeftide's advanced clinical development program. Fifteen clinical sites across Australia and New Zealand enrolled a total of 117 patients into the study. Patients were randomly assigned to three different treatment arms. In each treatment arm patients receive either pezadeftide or the vehicle (without pezadeftide) control. The assignment of vehicle versus active is blinded to both the patient and the investigator. Patients will be monitored at follow-up visits for the safety and efficacy of pezadeftide through to the end of the study. The study also collects patient satisfaction measures. Hexima expects this phase IIb clinical trial to represent its last large multi-centre clinical trial ahead of initiating a phase III program in third quarter of 2022. In preparation, Hexima expects to file an IND with FDA in fourth quarter of 2021 and then conduct an FDA-required small single-centre, maximal use, safety study in the US in first half of 2022.